October 22–26, 2025, AACR-NCI-EORTC International Conference

1)Discovery and development of a highly cooperative and potent pan-KRAS degrader.

2)Identification of first-in-class paralog selective SMARCA4 degraders for treatment of hematological and prostate malignancies.

3)Discovery of highly selective, potent and orally bio-available SMARCA2 degraders.